← Back to patent-cliff list
CAS 610798-18-0
N-(3-bromophenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-amine
Codes: ICOT-016
Application context (from source-drug indications)
Non-small cell lung cancerIcotinib HydrochlorideLung adenocarcinomaIcotinib HydrochlorideBronchial neoplasmIcotinib HydrochlorideLung cancerIcotinib HydrochlorideMetastatic breast cancerIcotinib HydrochloridePsoriasisIcotinib Hydrochloride
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Icotinib Hydrochloride | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(ethane-1,2-diylbis(oxy))bis(ethane-2,1-diyl) bis(4-methylbenzenesulfonate)→2-amino-4,5-dimethoxybenzoic acid→6,7-dimethoxyquinazolin-4(3H)-one→4-chloro-6,7-dimethoxyquinazoline→3-bromoaniline→N-(3-bromophenyl)-6,7-dimethoxyquinazolin-4-amine→4-((3-bromophenyl)amino)quinazoline-6,7-diol hydrochloride→N-(3-bromophenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-amine→ethynyltrimethylsilane
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.